Sunitinib

CHEMBL535 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

398.5 g/mol

LogP

2.6

Phase

4

A multi-targeted tyrosine kinase inhibitor that blocks several receptors on tumor cells and their blood supply simultaneously, used for kidney cancer, gastrointestinal stromal tumors, and certain pancreatic tumors. By cutting off the tumor's blood supply and directly inhibiting cancer cell growth signals, it helps slow or stop tumor progression.

Молекулярная масса

398,5000 g/mol

LogP

2,60

TPSA

77,20 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension Breast Cancer Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C

InChI

InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

Molecular Formula

C22H27FN4O2

HBD / HBA

3 / 4

Вращаемые Связи

7

Тяжёлые Атомы

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A multi-targeted tyrosine kinase inhibitor that blocks several receptors on tumor cells and their blood supply simultaneously, used for kidney cancer, gastrointestinal stromal tumors, and certain pancreatic tumors. By cutting off the tumor's blood supply and directly inhibiting cancer cell growth signals, it helps slow or stop tumor progression.

Yes, Sunitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL535. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5329102. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Sunitinib на PillFYI

Структура

Краткие Данные

Формула: C22H27FN4O2
Синонимы: 2

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.